Clinical Research 4.0: Bridging Global Standards with Local Realities and Expanding Patient Access with Rania Alshami, PDC CRO

About the Interviewee

Rania Alshami is the Chief Business and Strategy Officer of PDC CRO.

Rania Alshami, Ph.D., MBA, is Chief Business and Strategy Officer at PDC CRO, a regional clinical research organization headquartered in Dubai. With over two decades of leadership in business development, operations, and strategic growth, she has built a career at the intersection of science and commerce—advancing partnerships across biopharmaceutical, medtech, and healthcare sectors in the Middle East and North Africa. She is widely recognized for her expertise in negotiation, project management, and corporate strategy within the clinical research industry.

Dr. Alshami earned her Ph.D. in Cell Biology from the University of Delaware, where her doctoral work advanced fundamental insights into cellular and molecular mechanisms. During her time at Delaware, she also completed an MBA at the Alfred Lerner College of Business & Economics, equipping her with a unique dual perspective in science and management. She began her academic journey at the American University of Beirut, earning a B.Sc. in Biology with distinction.

Her professional career spans pivotal leadership roles across multiple continents. Prior to joining PDC CRO in 2022, she spent nearly eight years at Clinart MENA (Clinart MEA was acquired by CTI in 2020), serving first as Vice President of Operations in Dubai and later as Vice President of Business Development in Vancouver, where she spearheaded regional expansion and long-term client relationships. Earlier, she held senior posts at ERGOMED PLC, including Managing Director and Business Development Director, where she played a key role in driving clinical trial operations across the Middle East. She also served as Associate Director for Science Projects at Dubai Science Park, where she facilitated research partnerships and scientific initiatives.

Today, as Chief Business and Strategy Officer at PDC CRO, Dr. Alshami shapes organizational strategy, strengthens international collaborations, and advances innovative clinical trial delivery models. Her leadership reflects a rare integration of scientific training and executive vision, enabling her to bridge research and industry priorities. She continues to champion excellence in clinical research operations, while serving as a mentor and role model for emerging professionals navigating global biopharma and medtech ecosystems.

The Discussion

From Academia to Leadership: Charting the Path to PDC-CRO

[Engr. Dex Marco]: It’s such a pleasure to have you here with us, Dr. Rania. With a career spanning research, strategy, and clinical operations, your journey to becoming Chief Business and Strategy Officer at PDC-CRO reflects both depth and breadth of experience. Can you share the defining moments and motivations that led you to this leadership role, and how your background continues to shape your vision at PDC-CRO?

[Dr. Rania]: Thank you, Dex. My journey really started in academia, where I was immersed in the science of discovery. I loved the rigor of research, but more importantly, I felt a strong pull to translate that science into something that could actually change patients’ lives. Early on, I saw the gap between innovation happening globally and the limited access patients in the Middle East and Africa had to those treatments. That realization became a defining motivation for me.

When I transitioned from the lab into clinical research and business development, each role gave me a new lens: from understanding the molecular details, to navigating regulatory frameworks, to building partnerships that make large-scale impact possible. Along the way, there were moments that anchored my vision—working closely with regulatory agencies in the region, helping global biotech and pharma see the potential of MENA, and witnessing how quickly patients here can be enrolled in trials if the right infrastructure is in place.

Those experiences ultimately led me to PDC-CRO. For me, it was the natural culmination of my passion for science, strategy, and purpose: leading an organization dedicated to growing the clinical research industry in a region that needs it most. My background shapes my vision every day—I think like a scientist, act like a strategist, and lead with the conviction that our mission is about giving patients faster access to innovative treatments.

At PDC, my role isn’t just about business growth; it’s about building bridges between global innovation and regional patient needs. That is what drives me, and that is why I feel privileged to be in this position.

Driving Clinical Research Excellence in MEA

[Dex]: As clinical research in the Middle East and Africa grows in global relevance, PDC-CRO has played a pivotal role in elevating standards and ensuring regionally adapted solutions. How have you enhanced PDC-CRO’s ability to deliver high-quality, regionally relevant clinical trials across diverse markets?

[Dr. Rania]: From the beginning, my focus has been on shaping PDC-CRO into a partner that truly reflects the realities of the Middle East and Africa. I’ve worked to align global standards with local frameworks, build trusted networks with hospitals and investigators which in turn allowed us to provide reliable feasibility data, and invest in training and governance so our teams deliver trials of the highest quality. For me, it’s not just about running studies — it’s about making sure the region is recognized as a credible destination for cutting-edge research and that our patients are no longer left behind.

Adapting Strategies to Regional Market Dynamics

[Dex]: The MEA healthcare landscape is uniquely complex, with evolving regulatory frameworks, cultural considerations, and operational realities. How have you tailored business strategies to navigate these challenges while ensuring PDC-CRO’s competitive edge in the region?

[Dr. Rania]: The MEA region is complex, but I see that as our strength. I’ve focused on tailoring strategies rather than applying a one-size-fits-all model — engaging regulators early to navigate evolving frameworks, building culturally sensitive patient and site engagement approaches, and designing flexible operational models that adapt to each market. By combining regulatory agility, cultural awareness, and strong local partnerships, we’ve turned challenges into opportunities, positioning PDC-CRO as a trusted partner that delivers both global-quality research and regional relevance.

Building Strategic Partnerships Across the Region

[Dex]: Strategic collaborations are central to CRO success, particularly in emerging markets where alignment with local stakeholders is critical. Can you share your approach to establishing and maintaining partnerships with healthcare institutions, regulators, and pharmaceutical partners in MEA?

[Dr. Rania]: For me, partnerships are about people first. I’ve learned that in MEA, you don’t build trust overnight — you earn it by showing up, listening, and delivering on your word. With hospitals and investigators, we spend time understanding their challenges and making sure they feel empowered as part of the research process, not just as study sites. With regulators, we approach the relationship with openness and respect, because their confidence in us is what unlocks access for patients. And with pharmaceutical partners, we make it a point to bridge their global standards with the local realities we know so well. What sustains these collaborations is consistency — being transparent, being reliable, and always keeping the shared goal in mind: bringing innovative treatments to patients who need them most.

Developing Regional Talent and Teams

[Dex]: Beyond strategy and operations, long-term success in clinical research requires cultivating strong, skilled, and empowered teams. How have you mentored and developed cross-functional teams in MEA to achieve both operational excellence and sustainable growth?

[Dr. Rania]: I believe the real legacy of our work is not just the trials we deliver, but the people we develop along the way. In MEA, talent is incredibly promising but often underexposed to global best practices. We’ve made it a priority to mentor teams by giving them both responsibility and support — encouraging young professionals to take ownership of projects, while providing the training, governance, and guidance they need to succeed. We also focus on cross-functional collaboration, making sure our regulatory, clinical, and business development teams learn from each other and see how their contributions fit into the bigger picture. What motivates me most is watching team members grow in confidence, step into leadership roles, and carry forward the standards of excellence we’re building. For me, developing talent isn’t just about capacity; it’s about creating a sustainable ecosystem where clinical research in MEA can thrive for the long term.

Expanding PDC-CRO’s Regional Footprint

[Dex]: Growth in new therapeutic areas and geographies requires foresight and adaptability. What strategies have you employed to identify new opportunities and strengthen PDC-CRO’s presence across emerging markets in MEA?

[Dr. Rania]: We approach expansion by looking first at where the medical need is greatest — such as rare diseases and oncology — and then aligning that with markets where regulatory pathways and infrastructure make trials feasible. I spend time with local stakeholders to understand their needs and capabilities, and from there we design tailored entry strategies, whether through regional hubs or country-specific models. For me, growth isn’t just about entering new geographies; it’s about building credibility and ensuring PDC-CRO brings meaningful opportunities for patients across emerging markets in MEA.

Looking Ahead: Vision and Growth for PDC-CRO

[Dex]: As PDC-CRO continues to expand at the intersection of strategy, science, and regional leadership, your vision will help shape its trajectory. Where do you see PDC-CRO headed in the next few years, and what ambitions or transformations are you most excited to pursue as its Chief Business and Strategy Officer?

[Dr. Rania]: I see PDC-CRO continuing to grow as the trusted partner of choice for sponsors looking to bring innovative therapies to the MEA region. In the coming years, our focus is on strengthening our core as a science-driven, strategy-led CRO — expanding our reach, deepening our collaborations with regulators and healthcare institutions, and constantly raising the bar on quality and delivery. What excites me most is the transformation we are driving: positioning PDC-CRO not only as a service provider, but as a catalyst for building the regional research ecosystem and accelerating access to breakthrough treatments for patients. Our ambition is to put MEA firmly on the global clinical research map, and I believe PDC is uniquely positioned to achieve that.

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph., B.Sc. CpE

Editor-in-Chief, PharmaFEATURES

Join Proventa International’s Clinical Operations and Clinical Trial Supply Chain Europe Strategy Meeting at Crowne Plaza London Docklands, London, United Kingdom on the 9th of October 2025 to learn more about PDC CRO.